PLSE PULSE BIOSCIENCES, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1625101 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,637.2%
TTM net income YoY-12.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin26.8%
Operating margin-5,821.1%
Net margin-5,603.9%
FCF margin-4,263.9%
EBITDA margin-5,796.8%
Returns
ROE-60.6%
ROA-54.0%
ROIC (approx.)-95.2%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets8.9%
Debt / equity0.00x
Current ratio14.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-13.1%
Payout ratio—
Capex / revenue24.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $350,000 | $0 |
| Cost of revenue | $539,000 | $0 |
| Gross profit | -$189,000 | $0 |
| R&D expense | $44.72M | $32.34M |
| SG&A expense | $32.03M | $23.92M |
| Operating income | -$76.94M | -$56.26M |
| Pretax income | $72.80M | $53.60M |
| Income tax | $0 | $0 |
| Net income | -$72.78M | -$53.59M |
| EBITDA | -$76.53M | -$55.74M |
| EPS (basic) | -1.08 | -0.92 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $80.73M | $118.04M |
| Receivables | $274,000 | $0 |
| Inventory | $136,000 | $0 |
| Current assets | $83.42M | $119.45M |
| PP&E, net | $1.05M | $1.16M |
| Goodwill | $2.79M | $2.79M |
| Intangibles | $575,000 | $1.22M |
| Total assets | $94.54M | $132.46M |
| Current liabilities | $7.92M | $10.05M |
| Total liabilities | $13.88M | $17.60M |
| Shareholders' equity | $80.66M | $114.86M |
| Shares outstanding | 67.84M | 65.93M |
| Cash flow statement | ||
| Operating cash flow | -$54.12M | -$36.34M |
| Capital expenditure | $315,000 | $125,000 |
| Free cash flow | -$54.44M | -$36.47M |
| Investing cash flow | -$335,000 | -$125,000 |
| Financing cash flow | $17.15M | $110.14M |
| Depreciation & amortization | $406,000 | $512,000 |
| Stock-based compensation | $21.46M | $13.59M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.